|
[1]Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat[J].Am J Physiol Gastrointest Liver hysiol, 2001, 280 (1) ∶G68-74.
|
|
[2]Hongqun Liu, Lee Sam S. Tumor necrosis factor-alpha in cirrhotic cardiomyopathy[R].Journal of Hepatology, 2002, 36 (Suppl 1) ∶11.
|
|
[3]Fu H, Yang L, Liu X, et al. Alterations in the level of calcitonin gene related peptide and endothelin-1 in the cirrhotic rat heart[J].Hua Xi Yi Ke Da Xue Xue Bao, 2001, 32 (2) ∶200-1.
|
|
[4]Gaskari SA, Liu H, Moezi LiY, et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats[J].Br J Pharmacol, 2005, 146 (3) ∶315-23.
|
|
[5]Valeriano V, Funaro S, Lionetti R, et al.Modification of cardiacfunction in cirrhotic patients with and without ascites[J].Am J Gas-troenterol, 2000, 95∶3200-3205.
|
|
[6]Pozzi M, Redaelli E, Ratti L, et al.Time-course of diastolic dys-function in different stages of chronic HCVrelated liver diseases[J].Minerva Gastroentero Dietol, 2005, 51 (2) ∶179-86.
|
|
[7]Bal JS, Thuluvath PJ.Prolongation of QTc interval:relationship withetiology and severity of liver disease, mortality and liver transplanta-tion[J].Liver Int, 2003, 23∶243-8.
|
|
[8]Bernardi M, Clandra S, Colantoni A, et al. QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors[J].Hepatology, 1998, 27∶28-34.
|
|
[9]Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt[J].J Hepatol, 2003, 38∶461-467.
|
|
[10]Henriette Y, Jens H, Stefan Fuglsang, et al.Prolonged Q-Tc in-terval in mild portal hypertensive cirrhosis[J].Journal of Hepatolo-gy, 2005, 43∶637-644.
|
|
[11]Chaudhry V, Corse AM, Cornblath DR, et al.Autonomic and pe-ripheral neuropathy in chronic liver disease:a clinical and electro-physiologic study[J].Hepatology, 1999, 29∶1698-703.
|
|
[12]Moller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis[J].Scand J Clin Lab Invest, 2001, 61∶421-429.
|
|
[13]Therapondos G, Huang H, Lilly L, et al. Cirrhotic ardiomyopathy: Diagnosis using cardiac magnetic resonance (MR) [R].Journal of Hepatology, 2005, 42 (Suppl.2) ∶87.
|
|
[14]Wong F, Siu S, Liu P, et al.Brain natriuretic peptide:is it a pre-dictor of cardiomyopathy in cirrhosis?[J].Clin Sci (Lond) , 2001, 101 (6) ∶621-8.
|
|
[15]Hongqun Liu, Samuel SL.What happens to cirrhotic cardiomyopa-thy after liver transplantation?[J].Hepatology, 2005, 42 (5) ∶1203-1205.
|
|
[16]Henriksen JH, Bendtsen F, Hansen EF, et al.Acute non-selec-tive beta-adrenergic blockade reduces prolonged frequency-adjus-ted Q-T interval (QTc) in patients with cirrhosis[J].J Hepatol, 2004, 40∶239-46.
|
PDF下载 ( 171 KB)
本文二维码
下载:
